EP1737480A2 - Preparation combinee therapeutique contenant une proteine therapeutique - Google Patents

Preparation combinee therapeutique contenant une proteine therapeutique

Info

Publication number
EP1737480A2
EP1737480A2 EP05714189A EP05714189A EP1737480A2 EP 1737480 A2 EP1737480 A2 EP 1737480A2 EP 05714189 A EP05714189 A EP 05714189A EP 05714189 A EP05714189 A EP 05714189A EP 1737480 A2 EP1737480 A2 EP 1737480A2
Authority
EP
European Patent Office
Prior art keywords
nitrosation
nitrosated
nitroso
preparation according
thiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05714189A
Other languages
German (de)
English (en)
Inventor
Seth Hallström
Harald Gasser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1737480A2 publication Critical patent/EP1737480A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins

Definitions

  • the present invention relates to a pharmaceutical combination preparation which contains a therapeutic protein with SH groups which are nitrosated.
  • Nitrogen oxide is a gaseous molecule that is synthesized, among other things, in endothelial cells under normal physiological conditions.
  • the endothelium-dependent relaxation of vascular smooth muscles is mainly due to NO.
  • NO is therefore essential for the regulation of vascular tone.
  • NO is also involved in a number of physiological and pathophysiological processes. For example, NO deficiency in ischemia / reperfusion for vasoconstriction and edema formation (Huk et al., Circulation 96 (1997), 667-675; Hallström et al., Circulation 105 (2002), 3032-3038).
  • S-nitrosothiols form a group of potent, bioactive compounds that stabilize physiologically formed NO and potentiate its biological effects. NO therefore does not work in biological systems per se, but also via biologically active redox adducts of NO, such as S-nitrosoproteins, S-nitrosoamino acids or other S-nitrosothiol compounds.
  • the first mechanism is an electrophilic attack by a reactive NO species, the nitrosonium cation (NO + ), on the nucleophilic sulfur atom (Stamler et al., Science 258 (1992d), 1898-1902).
  • a second, controversial, mechanism is that S-nitrosation occurs through NO via peroxynitrite (ONOO " ) or NO 2 (Pryor et al, J. Org. Chem. 47 (1982), 156-159; Mohr et al., FEBS Lett. 348 (1994), 223-227; Wu et al., Am. J. Physiol.
  • the third, newer mechanism describes that S-nitrosations of thiol compounds (albumin, reduced glutathione ) is caused by dinitrosyl iron complexes (Boese et al., J. Biol. Chem. 270 (1995), 29244-29249).
  • the fourth mechanism is an S-transnitrosation reaction or S-nitroso exchange reaction in which an NO- Group is transferred from an S-nitroso compound to a second thiol compound in exchange for an H group (Feelisch et al, J. Cardiovasc. Pharmacol. 17 (1991), Suppl. 3, S25-S33; Field et al., JCS Chem Commun.
  • the object of the present invention is to increase the physiological effect of proteins which contain nitrosated SH groups.
  • a pharmaceutical combination preparation which contains a therapeutic protein with SH groups which are nitrosated and a thiol group-containing compound with an average molecular weight of at most 10,000.
  • thiol groups means sulfhydrile groups (-SH) and disulfide groups (-S-S-).
  • a preferred embodiment of the combination preparation according to the invention consists in that at least 90% of the SH groups present are nitrosated.
  • S-nitroso-albumin, S-nitroso-orosomucoid, S-nitroso-plasminogen activator, S-nitroso-fibrinogen, S-nitroso-Lys-plasminogen or S is particularly preferred as therapeutic protein with nitrosated SH groups -Nitroso hemoglobin included.
  • Reduced glutathione, L-cysteine, N-acetyl-cysteine, L-cysteinylglycine, ⁇ -glutamylcysteine, penicillamine, penicillamide are particularly preferred as the thiol group-containing compound. Contain N-acetyl-penicillamine, N-acetyl-penicillamide, homocysteine, captopril, dehydroliponic acid and / or their oxidized form, which is reduced after administration in vivo.
  • a further preferred embodiment of the pharmaceutical combination preparation according to the invention contains reduced glutathione as therapeutic protein with nitrosated SH groups S-nitroso-albumin and as a compound containing thiol groups.
  • a thio group-containing compound is a human one.
  • Compound occurring in blood and tissue particularly reduced glutathione, L-cysteine, L-cysteinylglycine, ⁇ -glutamylcysteine or dehydroliponic acid is particularly preferred.
  • a further embodiment of the pharmaceutical combination preparation according to the invention consists in that it contains a therapeutic protein obtained by nitrosation, in which the degree of nitrosation is composed of at least 90% S-nitrosation and a maximum of 10% N, O, C-nitrosation.
  • the pharmaceutical preparation according to the invention for the protein component can contain any proteins with a "free" thiol group, but proteins which can be used therapeutically for the purposes of the present invention are preferred, with physiological or blood-derived human proteins, such as albumin, orosomucoid and plasminogen activator (eg t-PA), fibrinogen, Lys-plasminogen or hemoglobin or also mixtures of such nitrosable or nitrosated proteins according to the invention are to be regarded as particularly preferred.
  • physiological or blood-derived human proteins such as albumin, orosomucoid and plasminogen activator (eg t-PA), fibrinogen, Lys-plasminogen or hemoglobin or also mixtures of such nitrosable or nitrosated proteins according to the invention are to be regarded as particularly preferred.
  • the pharmaceutical preparation according to the invention for the low-molecular thiol component can contain any low-molecular thiol compound, such as reduced glutathione, L-cysteine, N-acetyl-L-cysteine, L-cysteinylglycine, ⁇ -glutamylcysteine, penicillamine or amides, N-acetyl Penicillamine or amides, homocysteine, captopril (D-2-methyl-3-mercaptopropanoyl-L-proli) and reduced thioctic acid (dehydroliponic acid), but preferred are low molecular weight thiol compounds in the blood (plasma) such as reduced glutathione, L-cysteine , L-cysteinylglycine, ⁇ -glutamylcysteine and dehydroliponic acid.
  • low molecular weight thiol compounds in the blood (plasma) such as reduced glutathione, L-cy
  • the nitrosation is preferably carried out in such a way that only the freely available thiol groups are nitrosated and external nitrosations are avoided (equimolar nitrosation). This succeeds because primarily free SH groups are preferentially nitrosated and foreign nitrosations of the N, O, C atoms of the proteins take place only when there is an excess of nitrosating agent.
  • N- and C-nitroso compounds are suspected of being carcinogenic and also have different NO group release kinetics than S-nitroso compounds (see Zhang et al, J. Biol. Chem. 271 (24) (1996), 14271-14279), which is why in a preferred embodiment of the preparation according to the invention an N, 0, C-nitrosation degree of the proteins in the preparation of at most 10% is provided.
  • the proteins are preferably made available in purified form.
  • the degree of purity should preferably be such that the proteins can be administered pharmaceutically. Therefore, a protein for nitrosation with a degree of purity of at least 80%, in particular at least 90% (w / w%), based on protein, is provided for the protein component of the preparation according to the invention.
  • This purified protein can of course be formulated with other proteins into a pharmaceutical preparation.
  • the protein component in the preparation according to the invention can thus be a mixture of different equimolar nitrosated proteins, but it can also be a mixture of a non-nitrosated and an equimolar nitrosated protein.
  • the pharmaceutical preparation preferably contains S-nitroso human serum albumin as a protein component and reduced glutathione.
  • the pharmaceutical preparation preferably contains S-nitroso human serum albumin and hemoglobin.
  • the protein component is preferably made available in a higher purity than the non-nitrosated protein component.
  • human serum albumin is often administered in a purity of at least 80% of total protein as a pharmaceutical preparation. On an analog or higher degree of purity is also preferred for the S-nitrosated protein in the preparation. Therefore, after the nitrosation of the protein component for the nitrosated protein, an additional cleaning step is added.
  • the low molecular weight thiol compounds are preferably made available in purified form.
  • the degree of purity should preferably be suitable such that the low molecular weight thiol compound can be administered pharmaceutically in the preparation. Therefore, a degree of purity of at least 90%, in particular at least 95% w / w, based on the low molecular weight thiol compound is provided for the low molecular weight thiol compound of the preparation according to the invention. Of course, higher values are also preferred.
  • the pharmaceutical preparation according to the invention is preferably formulated in a pharmaceutically acceptable buffer solution, optionally with pharmaceutically acceptable stabilizers.
  • a pharmaceutically acceptable buffer solution optionally with pharmaceutically acceptable stabilizers.
  • sodium caprylate and / or sodium acetyltryptophanate is used as a stabilizer.
  • the preparations can also be provided as a spray or in a form suitable for topical use.
  • the preparation is provided in a form suitable for intravenous administration.
  • an IV-compatible preparation is characterized in particular by a low aggregate content or is free of aggregates.
  • the preparation according to the invention is therefore preferably in frozen or lyophilized form for storage purposes, in which it has a sufficiently long shelf life.
  • Both the low-molecular thiol compound and the nitrosated protein of the preparation according to the invention can be stored in a common or separate form.
  • the pharmaceutical preparation based on a protein with nitrosated thiol groups and a low molecular weight thiol compound is stable when stored separately in the lyophilized state.
  • the nitrosation can preferably be carried out in such a way that only after determining the “free” thiol content of the proteins is nitrosated to this proportion of “free” thiol groups and at the same time a low molecular weight
  • Both native thiol-containing proteins and thiol-containing proteins in which the “free” thiol groups are de-blocked by a specific method can be considered as the protein component.
  • the reactants or the reaction products are separated off after the nitrosation reaction and preferably to a quantitative extent or to a value below the detection limit.
  • the preparation according to the invention is also distinguished by a low aggregate content of the protein component.
  • the proportion of aggregates in the pharmaceutical preparation is below 20%, preferably below 10%, most preferably below 5%.
  • the nitrosation of the thiol-containing proteins is carried out under aerobic conditions, especially when working with acidic sodium nitrite.
  • the nitrosation is preferably carried out with an agent selected from HNO 2 , HNO, NOC1, NO + , RNO 2 , N 2 O 3 , N 2 O 4 , NO 2 - and NO radical, and in an acidic medium.
  • Organic NO donors can also be used.
  • the nitrosation should be carried out with an agent related to the release of NO equimolar to the "free" thiol group content of the protein.
  • a smaller ratio of agent for the nitrosation can also be used based on the thiol group content of the protein, but a ratio of 1: 1 is preferred.
  • an equimolar nitrosation means a minimal N- and The degree of nitrosation of the protein is guaranteed, and the duration of the nitrosation should be as short as possible.
  • the nitrosation is therefore preferably carried out for a period of from 2 minutes to several hours, preferably 30 minutes, at a temperature between 15-30 ° C., preferably at room temperature in an aqueous solution at pH 0.3 to 3.5, most preferably at pH 1.0 to 3.0, preferably in acid n range up to pH 1.5.
  • All types of protein fractions can be used as the starting material for the protein component, in particular also blood, plasma, serum, a plasma fraction or a purified protein fraction, but also culture supernatants or corresponding extracts. If, however, substances are contained in the starting material which can adversely affect the nitrosation step, such as, for example, low molecular weight thiol group-containing proteins or thiol group-containing compounds, these should preferably be separated off.
  • Preferred plasma fractions are those after the Colin fractionation and in particular the Cohn II and III fraction or the Cohn IV fraction.
  • a further purification step selected from precipitation, gel filtration, diafiltration, ultrafiltration and chromatographic purification, can be provided.
  • albumin is purified using ion exchange chromatography.
  • a purification step is carried out after the nitrosation of the protein, so that the substances used there do not influence one another and are also not present in the finished nitrosated protein component.
  • This purification step is preferably carried out in the form of a chromatographic purification, in particular by means of gel permeation chromatography
  • a treatment for inactivating viruses is preferably carried out before the nitrosation, but it can also be carried out terminally, ie after the nitrosation.
  • the protein component of the combination preparation according to the invention can be processed into a pharmaceutical-eutomatic preparation in a manner known per se.
  • the Hegel adheres to the formulation instructions (see Pharmacopoeia) for the non-nitrosated protein preparation.
  • the low molecular weight thiol compound preferably reduced glutathione or L-cysteine, is provided in a pharmaceutically administrable form as the pure substance b and is administered simultaneously with the purified, nitrosated protein component i.v. apply.
  • this combination preparation according to the invention includes the preparation of a combination preparation for improving perfusion or microcirculation, preferably in vital organs such as e.g. in the G-brain (cerebral ischemia, ischemic insult), in the heart (myocardial infarction), in the kidney or in the extremities or in the whole organism.
  • the combination preparation according to the invention can thus generally be used to prevent or treat ischemia and reperfusion damage.
  • the combination preparation according to the invention is also suitable for the treatment of shock, in particular traumatic, hypovolemic or hemorrhagic or neurogenic shock.
  • the combination preparation according to the present invention can be used in various surgical fields, for example in transplant surgery and in all surgical procedures with subsequent reperfusion. It is particularly suitable for the treatment and / or prophylaxis of restenosis after angioplasty.
  • the combination preparation can also be used for the treatment and / or prophylaxis of thrombotic conditions, ie those which are associated with platelet adhesion / aggregation.
  • the S-NO tissue plasminogen activator can be used as a thrombolytic agent.
  • the combination preparation is also used to relax the non-vascular, smooth muscles, e.g. the smooth muscles of the airways, usable. Therefore, the preparation according to the present invention can be used for the treatment and / or prophylaxis of respiratory diseases. It can also be useful for diagnosing and / or treating male erectile dysfunction.
  • a further, essentially preferred, medical use of the combination preparation according to the invention comprises the production of a combination preparation for the controlled reduction of blood pressure, e.g. in hypertensive crises (i.e. chronic or acute hypertension crises).
  • a higher dosage is used than for the prevention or treatment of ischemia and reperfusion damage.
  • the medical combination preparation is preferably provided with respect to the protein component in a dose which, except for albumin, corresponds to that of the non-nitrosated protein.
  • albumin as a protein component, the dose depends primarily on the medical indication. In the prevention or treatment of ischemia and reperfusion damage, depending on the S-nitrosograd of the albumin preparation, a dosage of 0.035-1.0 ⁇ mol / kg / h is recommended. When reducing blood pressure, higher doses should be used (e.g. up to 10 ⁇ mol / kg / h of S-NO albumin with an S-nitrosation level of ⁇ 26%).
  • a dose of 12-140 ⁇ mol / kg / h is recommended for the low molecular weight thiol compound (e.g. reduced glutathione).
  • the amount or dose to be administered depends on the requirements of the patient, for example on parameters such as hematocrit, oxygenation, mean arterial and venous blood pressure or pulmonary arterial pressure, and can vary considerably from case to case. Significantly lower doses can also be used for the platelet adhesion / anti-aggregation effect.
  • a particular advantage of the combination preparation according to the invention is that at least the same efficiency is achieved with proteins containing thiol groups as with Monopreparations of thiol group-containing proteins, in which the freely available thiol group was increased to 90% free SH groups per mole of protein by reductive pretreatment. In terms of process engineering, the reductive pretreatment is avoided. Equimolar nitrosation to the freely available thiol group guarantees the same degree of purity of the active component of the protein preparation (N-, C-, O-nitrosierang ⁇ 5%). Both albumin (4-5 g / dL plasma) and reduced L-glutathione ( ⁇ 5 ⁇ mol / L) are naturally occurring plasma components.
  • the naturally occurring transnitrosation reaction is limited by the physiologically occurring reduced L-glutathione level in the plasma.
  • reduced L-glutathione By providing reduced L-glutathione, the release of the active substance NO of the S -nitrosized protein component can even be controlled in a dose-dependent manner from the reduced L-glutathione.
  • combination preparation according to the invention can of course also be used for any indication of the non-nitrosated proteins in general, since their physiological effect is retained despite nitrosation.
  • conditions which require the provision of an increased NO content are preferred indications for the combination preparations according to the invention.
  • the ratio of free SH groups per mole of protein was determined using the Ellman reagent (Ellman G.L., Arch. Biochem. Biophys. 82 (1959), 70-77) according to Sedlak and Lindsay, Anal. Biochem. 25: 192-205 (1968).
  • the nitrosation of the albumin preparations was carried out equimolar to the content of the free SH groups (ratio: 1: 1 to a maximum of 1: 1, 2 molar to the determined value) with NaNO 2 in 0.2 mol / L HC1 at pH 1.5-2. 5 for a period of 15-30 min at room temperature. The mixture was then neutralized with 1 mol / L NaOH.
  • preparative gel permeation chromatography was carried out using a stationary phase of beads with a heteroporous, swollen network of a Toyopearl TSK HW 40 (F) gel. Elution was carried out with bidistilled water at 4 ° C. The purified fraction containing S-nitroso-albumin (S-NO-albumin / albumin) was then lyophilized.
  • the analysis can be carried out before or after the purification by means of preparative gel permeation chromatography.
  • preparative gel permeation chromatography With this method, if available, excess nitrosating agent and buffer substances are separated from the S-NO albumin / albumin using a gel permeation column (Toyopearl TSK HW-40-S). Subsequently, in a post-column derivatization process using the Saville reaction (Saville B., Analyst 83 (1958), 670-672), the NO group is selectively split off from the RS-NO by Hg 2+ . Simultaneously, the nitrite formed is photometrically detected at 541 nm by a color reaction (Griess reaction; Griess, Ber.Dtsch. Chem. Ges.
  • the chromatograms show equimolar nitrosated S-NO-HSA preparations with different S-nitroso degrees: a) human albumin nitrosated equimolar to the free SH group with a free SH group content per mol protein of 26%; b) human albumin nitrosated equimolar to the free SH group, which had a free SH group content per mole protein of 74% by reductive pretreatment; c) analogous to b), the nitrosation was not carried out equimolar but with a 6-fold molar excess of nitrosation agent.
  • Reduced glutathione produced by peptide synthesis with a purity of at least 95% was made available as a low molecular weight thiol compound.
  • example 1 the lowering of the mean arterial pressure by application of a combination preparation according to the invention consisting of a nitrosed serum albumin preparation and reduced glutathione is shown on the rabbit model.
  • a combination preparation according to the invention consisting of a nitrosed serum albumin preparation and reduced glutathione is shown on the rabbit model.
  • the effect of a nitrosated serum albumin preparation is shown, which was applied without reduced glutathione.
  • the rabbit was anesthetized, initiating anesthesia with ketaset (50 mg / kg; bolus) and xylasin (5 mg / kg; bolus) and with continuous infusion via the vena auricularis of Ketaset (35 mg / kg / h) and 5 mg Maintain xylasin (5 mg / kg / h) dissolved in physiological saline (5 mL / h).
  • FIG. 1 a shows the dose-dependent comparison of the lowering of the mean arterial pressure (MAP) in the rabbits after bolus administration of nitrosed serum albumin with and without simultaneous continuous infusion of reduced glutathione (2.2 ⁇ mol / kg / min).
  • Infusion: Vena femoralis (n 3 per data point; mean ⁇ standard deviation).
  • Fig. 1b is a representative example of the lowering of the mean arterial pressure with a bolus infusion of 0.1 ⁇ mol / kg S-NO-HSA with and without continuous infusion of reduced glutathione (2.2 ⁇ mol / kg / min).
  • FIG. 1e is a representative example of the lowering of the mean arterial pressure by bolus injections of 0.1 ⁇ mol / kg S-NO-HSA with variable concentrations of GSH in vivo. Infusion: femoral vein.
  • FIG. 1f is a representative example of the lowering of the mean arterial pressure by simultaneous, continuous infusion of 0.05 ⁇ mol / kg / min S-NO-HSA with increasing concentration of reduced glutathione (a: 0.0 ⁇ mol GSH / kg / min , b: 0.1 ⁇ mol GSH / kg / min, c: 0.3 ⁇ mol GSH / kg / min).
  • S-NO-HSA was infused through the jugular vein and reduced glutathione through the second auricular vein (or vena femoralis).
  • Example 2 shows the potentiation of the NO release of a nitrosated serum albumin preparation by providing a low-molecular thiol compound using the example of reduced glutathione. The NO concentration was measured in vitro.
  • FIG. 2b shows a representative example of the in vitro measurement of the potentiation of the NO release of a nitrosated serum albumin preparation by reduced glutathione.
  • Example 3 shows the effect of a preferred embodiment of the combination preparation according to the invention on platelet aggregation.
  • the platelet aggregation was carried out with human platelet-rich plasma (TRP) in a dual-channel chronolog aggregometer in principle according to the method of Born (1969).
  • TRP human platelet-rich plasma
  • the exact dose of collagen for which collagen-induced aggregation ( ⁇ l ⁇ g collagen / mL TRP) was determined (95-100% inhibition of collagen-induced aggregation by 300 ⁇ mol / L acetylsalicylic acid).
  • increasing concentrations of reduced glutathione were primarily pre-incubated with TRP in the aggregometer for one minute and S-NO-HSA (2-4 ⁇ mol / L; concentration that causes 20% inhibition of collagen-induced aggregation) was added after one minute.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une préparation combinée thérapeutique contenant une protéine thérapeutique comportant des groupes SH, qui sont nitrosés, ainsi qu'un composé contenant des groupes thiol, de poids moléculaire moyen maximal de 10.000.
EP05714189A 2004-03-29 2005-03-24 Preparation combinee therapeutique contenant une proteine therapeutique Withdrawn EP1737480A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT5562004 2004-03-29
PCT/AT2005/000107 WO2005092362A2 (fr) 2004-03-29 2005-03-24 Preparation combinee therapeutique contenant une proteine therapeutique

Publications (1)

Publication Number Publication Date
EP1737480A2 true EP1737480A2 (fr) 2007-01-03

Family

ID=34962264

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05714189A Withdrawn EP1737480A2 (fr) 2004-03-29 2005-03-24 Preparation combinee therapeutique contenant une proteine therapeutique

Country Status (3)

Country Link
US (2) US8518869B2 (fr)
EP (1) EP1737480A2 (fr)
WO (1) WO2005092362A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525370A (ja) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法
GB201506236D0 (en) * 2015-04-13 2015-05-27 Jellagen Pty Ltd Modified collagen, methods of manufacture thereof
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
CN117964732A (zh) 2015-08-07 2024-05-03 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
BR102016018074A2 (pt) 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
BR112022008817A2 (pt) 2019-11-27 2022-07-26 Alx Oncology Inc Terapias combinadas para tratamento de câncer
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002810A1 (fr) * 1989-08-09 1991-03-07 The Children's Medical Center Corporation Agents d'oxydation de nmda protegeant les neurones contre les lesions
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
AT405135B (de) * 1997-01-17 1999-05-25 Immuno Ag Präparation umfassend thiolgruppen-hältige proteine
WO2001065935A1 (fr) 2000-03-08 2001-09-13 Yoram Vodovotz Solution pour perfusion du rein contenant un donneur d'oxyde nitrique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005092362A2 *

Also Published As

Publication number Publication date
US8518869B2 (en) 2013-08-27
WO2005092362A2 (fr) 2005-10-06
WO2005092362A3 (fr) 2006-02-23
US20070238641A1 (en) 2007-10-11
US20140051634A1 (en) 2014-02-20

Similar Documents

Publication Publication Date Title
DE69231666T2 (de) Die nitrosylierung von enzym-sh gruppen als eine therapeutische massnahme
Quinlan et al. Albumin: biochemical properties and therapeutic potential
Troncy et al. Extra-pulmonary effects of inhaled nitric oxide in swine with and without phenylephrine
DE69533940T2 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
DE68905387T2 (de) Aminosäure-Nahrungsmittelzusammensetzungen.
DE602004008927T2 (de) Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
US20140051634A1 (en) Pharmaceutical combined preparation containing a therapeutic protein
EP0712626B1 (fr) Utilisation de l'acide R,S-(+/-)-alpha-lipoique, R-(+)-alpha-lipoique, S-(-)-alpha-lipoique en forme réducée ou oxidée ou des métabolites ainsi que leurs sels, esters, amides pour la manufacture des agents rhéologiques
DE19628705A1 (de) Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe
JP2003524630A (ja) Ｎｏ基化合物で心肺疾病を処置する方法
GB1562871A (en) Pharmaceutical composition
CA2230448A1 (fr) Composition pour anesthesie locale
DE19538687A1 (de) Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
DE69823211T2 (de) No-modifizierte Hämoglobine und Verwendung dafür
EP0853944B1 (fr) Préparations contenant des protéines à groupements thiol
DE10212321A1 (de) Verwendung eines oder mehrerer von Plasma und Zellwandbestandteilen befreiten natürlichen oder modifizierten Sauerstoffbinder zur externen Behandlung offener, insbesondere chronischer Wunden
US7166577B2 (en) Albumin having enhanced antimicrobial activity
EP2217619B1 (fr) Protéine cyclique exempte de cystéine
WO1992003146A1 (fr) Melange de composes de glutathion et d'anthocyane actif en therapeutique
EP2988768B1 (fr) Lyophilisat comprenant un peptide cyclique de formule x1-gqretpegaeakpwy-x2 pout le traitement de l'oedeme du poumon
Tibballs The role of nitric oxide (formerly endothelium-derived relaxing factor-EDRF) in vasodilatation and vasodilator therapy
EP2747756B1 (fr) Sels métabolisables et leur utilisation pour le diagnostic et la thérapie
Stuesse et al. Hemodynamic effects of S-nitrosocysteine, an intravenous regional vasodilator
Troncy et al. Comparison of the effect of inhaled nitric oxide and intravenous nitroglycerine on hypoxia-induced pulmonary hypertension in pigs
DE69130483T2 (de) Verbesserter blutersatz

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060915

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160510

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171003